Login  |  Register  |  July 31, 2010
 You are here:- Home
________News________ Minimize
 

Scout Diagnostics Formed - Saturday, March 10, 2007
Scout Diagnostics, LLC has been formed to commercialize technology developed at the University of Kentucky to positively identify Alzeihmer Disease in patients.  This new technology holds tremendous promise for the early detection of the disease which would allow for treatments to begin early, thus improving the chances of a hopeful outcome. 
 
March 2008- Scout Diagnostic founders organize CoPlex Therapeutics, LLC
CoPlex’s mission is to develop a therapeutic drug that targets and attacks the biomarker identified by Scout’s diagnostic tests. CoPlex researchers have already identified several candidate compounds and are rigorously evaluating the potential of each.  
June 3, 2008- Scout Diagnostics has manuscript published in Neurology
As the leading clinical neurology journal worldwide, Neurology is directed to physicians concerned with diseases and conditions of the nervous system. The journal is at the forefront in disseminating cutting-edge, peer-reviewed information to the neurology community worldwide.
 
Chandler Announces $100,000 for Alzheimer's Research - Wednesday, July 04, 2007
WASHINGTON (June 14, 2007) - Congressman Chandler announced today that Scout Diagnostics, a Kentucky-based company, will receive over $100,000 in grant funding from the U.S. Department of Health and Human Services for the development of a diagnostic test for Alzheimer's disease.  Located in Lexington, Kentucky, Scout Diagnostics was spawned from the University of Kentucky's incubator for technology transfer.

"Alzheimer's disease affects nearly five million Americans and their families and is the fourth leading cause of death in the United States," said Congressman Ben Chandler.  "Substantial funds must be invested in Alzheimer's research if there is to be significant progress in fighting the disease."

Scout Diagnostics was founded by John Beran in 2006 to develop and market a new Alzheimer's diagnostic test.  The test identifies certain protein complexes which serve as biomarkers used to detect Alzheimer's disease prior to clinical diagnosis.  Scout Diagnostics is preparing clinical studies in anticipation of filing for Food and Drug Administration approval of this test.  The company will use the funding to begin these clinical studies.

"I am pleased that Scout Diagnostics has been awarded this grant.  It is crucial that we provide the necessary resources for researchers and scientists like those at Scout Diagnostics to work toward ways to better treat-and someday find a cure for-debilitating diseases such as Alzheimer's," said Chandler.  "I am proud that Kentucky's own researchers and scientists are leading the way in this important effort."

 
December 2007- Scout researchers find Alzheimer's biomarker in blood serum.
The company moves forward with plans to commercially develop a blood based Alzheimer’s diagnostic test. This test will likely serve as an Alzheimer’s screening device, where by a positive result can be confirmed with Scout’s Cerebral Spinal Fluid (CSF) Diagnostic test. 
June 3, 2008 Scout Diagnostics has manuscript published in Neurology
As the leading clinical neurology journal worldwide, Neurology is directed to physicians concerned with diseases and conditions of the nervous system. The journal is at the forefront in disseminating cutting-edge, peer-reviewed information to the neurology community worldwide. 
June 3, 2008 Scout Diagnostics has manuscript published in Neurology
As the leading clinical neurology journal worldwide, Neurology is directed to physicians concerned with diseases and conditions of the nervous system. The journal is at the forefront in disseminating cutting-edge, peer-reviewed information to the neurology community worldwide. 
December 2007- Scout researchers find Alzheimer's biomarker in blood serum.
The company moves forward with plans to commercially develop a blood based Alzheimer’s diagnostic test. This test will likely serve as an Alzheimer’s screening device, where by a positive result can be confirmed with Scout’s Cerebral Spinal Fluid (CSF) Diagnostic test. 
March 2008- Scout Diagnostic founders organize CoPlex Therapeutics, LLC
CoPlex’s mission is to develop a therapeutic drug that targets and attacks the biomarker identified by Scout’s diagnostic tests. CoPlex researchers have already identified several candidate compounds and are rigorously evaluating the potential of each.  
June 3, 2008- Scout Diagnostics has manuscript published in Neurology
As the leading clinical neurology journal worldwide, Neurology is directed to physicians concerned with diseases and conditions of the nervous system. The journal is at the forefront in disseminating cutting-edge, peer-reviewed information to the neurology community worldwide.
 
Chandler Announces $100,000 for Alzheimer's Research - Wednesday, July 04, 2007
WASHINGTON (June 14, 2007) - Congressman Chandler announced today that Scout Diagnostics, a Kentucky-based company, will receive over $100,000 in grant funding from the U.S. Department of Health and Human Services for the development of a diagnostic test for Alzheimer's disease.  Located in Lexington, Kentucky, Scout Diagnostics was spawned from the University of Kentucky's incubator for technology transfer.

"Alzheimer's disease affects nearly five million Americans and their families and is the fourth leading cause of death in the United States," said Congressman Ben Chandler.  "Substantial funds must be invested in Alzheimer's research if there is to be significant progress in fighting the disease."

Scout Diagnostics was founded by John Beran in 2006 to develop and market a new Alzheimer's diagnostic test.  The test identifies certain protein complexes which serve as biomarkers used to detect Alzheimer's disease prior to clinical diagnosis.  Scout Diagnostics is preparing clinical studies in anticipation of filing for Food and Drug Administration approval of this test.  The company will use the funding to begin these clinical studies.

"I am pleased that Scout Diagnostics has been awarded this grant.  It is crucial that we provide the necessary resources for researchers and scientists like those at Scout Diagnostics to work toward ways to better treat-and someday find a cure for-debilitating diseases such as Alzheimer's," said Chandler.  "I am proud that Kentucky's own researchers and scientists are leading the way in this important effort."

 
Scout Diagnostics Formed - Saturday, March 10, 2007
Scout Diagnostics, LLC has been formed to commercialize technology developed at the University of Kentucky to positively identify Alzeihmer Disease in patients.  This new technology holds tremendous promise for the early detection of the disease which would allow for treatments to begin early, thus improving the chances of a hopeful outcome. 
 
 
Developing the tools for early detection...
Scout Diagnostics is developing a new diagnostic tool that will allow the very early determination of Alzheimer Disease in patients.  This exciting new tool will allow researchers to test the efficacy of new treatments and will eventually allow for an early diagnosis, and thus begin treatment in the early stages of the disease, where treatments can be the most beneficial. 

Please take some time to browse this site and learn more about this exciting new technology and how it could be applied to your research efforts, or in your clinical setting.  Early diagnosis with high sensitivity and specificity is critical to the long term management of this devastating disease. 
Quick facts about Alzheimer's Disease
Initially described by Alois Alzheimer in 1907

Affects ~ 4 million Americans

Fourth leading cause of death in the US

May affect 9 million Americans by 2040

May begin 20 to 30 years before onset of clinical symptoms
Copyright 2009 by Scout Diagnostics, LLC   |  Sheltowee  |  Terms Of Use  |  Privacy Statement